Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Aldeyra Therapeutics, Inc. (ALDX)
|
Add to portfolio |
|
|
|
| Price: |
$11.36
| | Metrics |
| OS: |
58.6
|
M
| |
|
|
| Market cap: |
$666
|
M
| |
|
|
|
Net debt:
|
$5.89
|
M
| |
|
|
|
EV:
|
$672
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($61.4)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | | | | | | |
| Selling, general and administrative | 0.0 | 0.0 | 1.8 | | | | | |
| Research and development | | | | 44.4 | 29.8 | 16.3 | 13.2 | 7.6 |
| General and administrative | 0.0 | 0.0 | | 12.2 | 9.9 | 6.2 | 5.5 | 4.4 |
| EBIT | -61.4 | -59.3 | -37.9 | -56.5 | -39.7 | -22.5 | -18.7 | -12.0 |
| EBIT margin | | | | | | | | |
| Pre-tax income | -62.0 | -57.8 | -38.0 | -62.1 | -38.9 | -22.3 | -18.7 | -12.1 |
| Income taxes | 0.0 | 0.0 | -0.5 | 1.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 1.3% | | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -62.0 | -57.8 | -37.6 | -60.8 | -38.9 | -22.3 | -18.7 | -12.1 |
| Net margin | | | | | | | | |
| |
| Diluted EPS | ($1.06) | ($1.07) | ($1.11) | ($2.24) | ($1.79) | ($1.40) | ($1.65) | ($1.40) |
| Shares outstanding (diluted) | 58.4 | 54.0 | 34.0 | 27.1 | 21.7 | 15.9 | 11.4 | 8.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|